Intraethnic variation in steroid-5-alpha-reductase polymorphisms in prostate cancer patients: a potential factor implicated in 5-alpha-reductase inhibitor treatment

被引：0

作者：

Alberto Henriquez-Hernandez, Luis ^{[1
,2
,3
]}

Valenciano, Almudena ^{[2
]}

Foro-Arnalot, Palmira ^{[4
]}

Jesus Alvarez-Cubero, Maria ^{[5
,6
]}

Manuel Cozar, Jose ^{[7
]}

Francisco Suarez-Novo, Jose ^{[8
]}

Castells-Esteve, Manel ^{[8
]}

Fernandez-Gonzalo, Pablo ^{[9
]}

De-Paula-Carranza, Belen ^{[9
]}

Ferrer, Montse ^{[10
]}

Guedea, Ferran ^{[11
]}

Sancho-Pardo, Gemma ^{[12
]}

Craven-Bartle, Jordi ^{[12
]}

Jose Ortiz-Gordillo, Maria ^{[13
]}

Cabrera-Roldan, Patricia ^{[13
]}

Herrera-Ramos, Estefania ^{[14
,15
]}

Rodriguez-Gallego, Carlos ^{[14
,15
]}

Lara, Pedro C. ^{[1
,2
,3
]}

机构：

[1] Hosp Univ Gran Canaria Dr Negrin, Dept Radiat Oncol, Las Palmas Gran Canaria 35010, Spain

[2] Inst Canario Invest Canc, Las Palmas Gran Canaria 38204, Spain

[3] Univ Las Palmas Gran Canaria, Clin Sci Dept, Las Palmas Gran Canaria 35016, Spain

[4] Hosp Esperanza, Inst Oncol Radioterap, Barcelona 08003, Spain

[5] Univ Granada, Fac Med, Legal Med & Toxicol Dept, Lab Genet Identificat, Granada 18012, Spain

[6] Pfizer Univ Granada Andalusian Govt Ctr Genom & O, GENYO, Granada 18016, Spain

[7] Hosp Univ Virgen de las Nieves, Dept Urol, Granada 18014, Spain

[8] Hosp Univ Bellvitge, Dept Urol, Lhospitalet De Llobregat 08907, Spain

[9] Onkologikoa, Dept Radiat Oncol, Guipuzcoa 20014, Spain

[10] Inst Recerca Hosp del Mar IMIM, Hlth Serv Res Grp, Barcelona 08003, Spain

[11] ICO, Dept Radiat Oncol, Lhospitalet De Llobregat 08907, Spain

[12] Hosp Santa Creu & Sant Pau, Dept Radiat Oncol, Barcelona 08026, Spain

[13] Hosp Univ Virgen del Rocio, Dept Radiat Oncol, Seville 41013, Spain

[14] Hosp Univ Gran Canaria Dr Negrin, Dept Immunol, Las Palmas Gran Canaria 35010, Spain

[15] Univ Las Palmas Gran Canaria, Dept Med & Surg Sci, Las Palmas Gran Canaria 35016, Spain

来源：

JOURNAL OF GENETICS | 2015年 / 94卷 / 02期

关键词：

5-alpha-reductase polymorphism; 5-alpha-reductase inhibitors; OpenArray; prostate cancer; pharmacoethnicity; SRD5A2; RISK; CHEMOPREVENTION; DUTASTERIDE; POPULATION; TYPE-2;

D O I：

暂无

中图分类号：

Q3 [遗传学];

学科分类号：

071007 ; 090102 ;

摘要：

引用

页码：335 / 341

页数：7

共 24 条

[1] High-throughput genotyping system as a robust and useful tool in oncology: Experience from a single institution
Alberto Henriquez-Hernandez, Luis
Valenciano, Almudena
Herrera-Ramos, Estefania
Lloret, Marta
Riveros-Perez, Alba
Lara, Pedro C.
[J]. BIOLOGICALS, 2013, 41 (06) : 424 - 429
[2] Polymorphisms in DNA-Repair Genes in a Cohort of Prostate Cancer Patients from Different Areas in Spain: Heterogeneity between Populations as a Confounding Factor in Association Studies
Alberto Henriquez-Hernandez, Luis
Valenciano, Almudena
Foro-Arnalot, Palmira
Jesus Alvarez-Cubero, Maria
Manuel Cozar, Jose
Francisco Suarez-Novo, Jose
Castells-Esteve, Manel
Ayala-Gil, Adriana
Fernandez-Gonzalo, Pablo
Ferrer, Montse
Guedea, Ferran
Sancho-Pardo, Gemma
Craven-Bartle, Jordi
Jose Ortiz-Gordillo, Maria
Cabrera-Roldan, Patricia
Herrera-Ramos, Estefania
Lara, Pedro C.
[J]. PLOS ONE, 2013, 8 (07):
[3] Ambrosio B, 2010, COLLEGIUM ANTROPOL, V34, P1215
[4] Effect of Dutasteride on the Risk of Prostate Cancer.
Andriole, Gerald L.
Bostwick, David G.
Brawley, Otis W.
Gomella, Leonard G.
Marberger, Michael
Montorsi, Francesco
Pettaway, Curtis A.
Tammela, Teuvo L.
Teloken, Claudio
Tindall, Donald J.
Somerville, Matthew C.
Wilson, Timothy H.
Fowler, Ivy L.
Rittmaster, Roger S.
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2010, 362 (13) : 1192 - 1202
[5] Safety and tolerability of the dual 5α-reductase inhibitor dutasteride in the treatment of benign prostatic hyperplasia
Andriole, GL
Kirby, R
[J]. EUROPEAN UROLOGY, 2003, 44 (01) : 82 - 88
[6] [Anonymous], 2012, SNPSTATS SNPMATRIX X
[7] Haploview: analysis and visualization of LD and haplotype maps
Barrett, JC
Fry, B
Maller, J
Daly, MJ
[J]. BIOINFORMATICS, 2005, 21 (02) : 263 - 265
[8] Low-activity V89L variant in SRD5A2 is associated with aggressive prostate cancer risk:: An explanation for the adverse effects observed in chemoprevention trials using 5-alpha-reductase inhibitors
Cussenot, Oliuier
Azzouzi, Abdel-Rahmene
Nicolaiew, Nathalie
Mangin, Philippe
Cormier, Luc
Fournier, Georges
Valeri, Antoine
Cancel-Tassin, Geraldine
[J]. EUROPEAN UROLOGY, 2007, 52 (04) : 1082 - 1089
[9] Finasteride in the treatment of clinical benign prostatic hyperplasia: A systematic review of randomised trials
Edwards J.E.
Moore R.A.
[J]. BMC Urology, 2 (1) : 1 - 17
[10] The 5α-reductase type II A49T and V89L high-activity allelic variants are more common in men with prostate cancer compared with the general population
Giwercman, YL
Abrahamsson, PA
Giwercman, A
Gadaleanu, V
Ahlgren, G
[J]. EUROPEAN UROLOGY, 2005, 48 (04) : 679 - 685

← 1 2 3 →